Phase 2 data and FDA-aligned Phase 3 design in hand for neuropathic corneal pain; approval rests on NEPTUNE trial replicating the Phase 2 effect in a single pivotal study

Bull

NEPTUNE enrolls on schedule with the FDA-aligned 111-patient, single-dose, 2:1 randomization design, and urcosimod replicates the Phase 2 signal — delivering a statistically significant ≥2-point VAS improvement at Week 12. A clean readout on this single pivotal study, potentially supported by a Breakthrough Therapy Designation, would position OKYO for NDA submission and represent a transformative value inflection for a company with no approved products.

Bear

The most likely failure modes are enrollment difficulty given neuropathic corneal pain is a rare, under-diagnosed condition with no validated referral network, and effect size dilution in a broader, less-selected patient population relative to the 18-patient Phase 2 cohort. A single pivotal trial design leaves no statistical safety net — a negative or inconclusive primary endpoint result would likely be program-ending without a clear path to recovery.